Supplementary Table 1. Examination Of The Relationship Between TE Status Of The Cases And Demographic, Clinical, And Laboratory Data

Parameter	Category	TE Present (*n* = 36)	TE Absent (*n* = 167)	*P* value
Age, y		40.61 ± 14.51	40.10 ± 11.88	.821
Gender	Male	12 (33.3)	85 (50.9)	.056
	Female	24 (66.7)	82 (49.1)	.056
Factor V Leiden mutation	Absent	31 (86.1)	135 (80.8)	.029
	Homozygous	3 (8.3)	3 (1.8)	.029
	Heterozygous	2 (5.6)	29 (17.4)	.029
Factor II mutation	Absent	29 (80.6)	157 (94.0)	.053
	Homozygous	2 (5.6)	2 (1.2)	.053
	Heterozygous	5 (13.9)	8 (4.8)	.053
MTHFR A1298C mutation	Absent	10 (27.8)	87 (52.1)	.010
	Homozygous	10 (27.8)	20 (12.0)	.010
	Heterozygous	16 (44.4)	60 (35.9)	.010
PAI-1	Absent	18 (50.0)	70 (41.9)	.674
	Homozygous	5 (13.9)	27 (16.2)	.674
	Heterozygous	13 (36.1)	70 (41.9)	.674
Factor XIII mutation	Absent (5G/5G)	9 (25.0)	33 (19.8)	.066
	Homozygous (4G/4G)	22 (61.1)	78 (46.7)	.066
	Heterozygous (4G/5G)	5 (13.9)	56 (33.5)	.066
Homozygous mutation	Absent	13 (36.1)	96 (57.5)	.020
	Present	23 (63.9)	71 (42.5)	.020
Mortality status	Absent	36 (100.0)	165 (98.8)	.998
	Present	0 (0.0)	2 (1.2)	.998
Hospitalization status	Present	2 (5.6)	107 (64.1)	< .001
	Absent	34 (94.4)	60 (35.9)	< .001
PLT (x10³/mm³)		296.31 ± 121.84	276.96 ± 90.39	.277
PT, sec		12.24 ± 2.51	12.41 ± 5.01	.841
aPTT, sec		25.35 ± 14.80	24.27 ± 11.14	.621
INR		1.01 ± 0.22	1.05 ± 0.68	.724
D-Dimer, µg/L		3604.69 ± 3898.39	826.69 ± 930.74	< .001

TE, Thrombo-embolism; SD, Standard deviation; n, Number of cases; PLT, Platelet; PT, Prothrombin time; aPTT, Activated partial thromboplastin time test; INR, International normalized ratio; P, Pearson x^2 test; t, Independent t test; F, Fisher's exact test.

Supplementary Table 2. Comparison Of TE Status Of The Cases With Demographic, Clinical, And Laboratory Data According To COVID-19 RT-PCR Results

Parameter	Category	COVID-19 (+) Cases (n = 98)		P	COVID-19 (-) Cases (n = 105)		P
		TE Present (n = 28)	TE Absent (n = 70)		TE Present (n = 8)	TE Absent (n = 97)	
Age, y	Age, y	39.82 ± 15.43	40.60 ± 11.38	.784t	43.38 ± 11.09	39.73 ± 12.27	.419t
Gender	Male	11 (39.3)	38 (54.3)	.180	1 (12.5)	47 (48.5)	.050
	Female	17 (60.7)	32 (45.7)	.180	7 (87.5)	50 (51.5)	.050
Factor V Leiden Mutation	Absent	25 (29.8)	59 (70.2)	.423	6 (7.3)	76 (92.7)	.064
	Homozygous	2 (40.0)	3 (60.0)	.423	1 (100.0)	0 (0.0)	.064
	Heterozygous	1 (11.1)	8 (8.9)	.423	1 (4.5)	21 (95.5)	.064
Factor II Mutation	Absent	21 (25.0)	63 (75.0)	.159	8 (7.8)	94 (92.2)	.997
	Homozygous	2 (50.0)	2 (50.0)	.159	0 (0.0)	0 (0.0)	.997
	Heterozygous	5 (50.0)	5 (50.0)	.159	0 (0.0)	3 (100.0)	.997
MTHFR A1298C Mutation	Absent	7 (15.6)	38 (84.4)	.007	3 (5.8)	49 (94.2)	.725
	Homozygous	9 (56.3)	7 (43.8)	.007	1 (7.1)	13 (92.9)	.725
	Heterozygous	12 (32.4)	25 (67.6)	.007	4 (10.3)	35 (89.7)	.725
PAI-1	Absent	14 (34.1)	27 (65.9)	.508	4 (8.5)	43 (91.5)	.481
	Homozygous	5 (29.4)	12 (70.6)	.508	0 (0.0)	15 (100.0)	.481
	Heterozygous	9 (22.5)	31 (77.5)	.508	4 (9.3)	39 (90.7)	.481
Factor XIII Mutation	Absent (5G/5G)	3 (9.7)	28 (90.3)	.015	3 (13.0)	20 (87.0)	.534
	Homozygous (4G/4G)	6 (31.6)	13 (68.4)	.015	3 (5.8)	49 (94.2)	.534
	Heterozygous (4G/5G)	19 (39.6)	29 (60.4)	.015	2 (6.7)	28 (93.3)	.534
Homozygous Mutation	Absent	10 (35.7)	42 (60.0)	.030	3 (37.5)	54 (55.7)	.321
	Present	18 (64.3)	28 (40.0)	.030	5 (62.5)	43 (44.3)	.321
Mortality Status	Absent	28 (100.0)	69 (98.6)	.997	8 (100.0)	96 (99.0)	.998
	Present	0 (0.0)	1 (1.4)	.997	0 (0.0)	1 (1.0)	.998
Hospitalization Status	Absent	2 (7.1)	52 (74.3)	< .001	0 (0.0)	55 (56.7)	.002
	Present	26 (92.9)	18 (25.7)	< .001	8 (100.0)	42 (43.3)	.002
PLT, x10^3/mm^3		311.82 ± 131.4	294.09 ± 111.2	.500t	242.0 ± 57.24	264.3 ± 69.7	.375
PT (sec)		12.53 ± 2.77	12.88 ± 6.43	.778	11.23 ± 0.59	12.07 ± ,65	.520
aPTT (sec)		26.03 ± 16.69	24.95 ± 12.45	.726	22.95 ± 3.49	23.77 ± 10.1	.820
INR		1.03 ± 2.54	1.12 ± 0.96	.631	0.95 ± 0.05	1.00 ± 0.34	.645
D-Dimer, µg/L		4310.7 ± 4153.3	1116.6 ± 1272.6	< .001	1133.4 ± 690.3	617.47 ± 477.8	.006

TE, Thrombo-embolism; SD, Standard deviation; n, Number of cases; PLT, Platelet; PT, Prothrombin time; aPTT, Activated partial thromboplastin time test; INR, International normalized ratio; P, Pearson chi-square test; t, Independent t test; F, Fisher's exact test.

Supplementary Table 3. Comparison of D-Dimer levels according to Covid-19 RT-PCR positivity and TE status

Parameter	Mean ± SD	*P* value	95% CI
Covid-19 (+) + TE (+)	4310.79 ± 4153.34	<0.001	2426.77–3961.60
Covid-19 (+) + TE (-)	1116.60 ± 1272.61	<0.001	2426.77–3961.60
Covid-19 (+) + TE (+)	4310.79 ± 4153.34	<0.001	1801.56–4553.26
Covid-19 (-) + TE (+)	1133.38 ± 690.25	<0.001	1801.56–4553.26
Covid-19 (+) + TE (+)	4310.79 ± 4153.34	<0.001	2957.04–4429.58
Covid-19 (-) + TE (-)	617.47 ± 477.88	<0.001	2957.04–4429.58
Covid-19 (+) + TE (-)	1116.60 ± 1272.61	.979	1264.08–1297.63
Covid-19 (-) + TE (+)	1133.38 ± 690.25	.979	1264.08–1297.63
Covid-19 (+) + TE (-)	1116.60 ± 1272.61	.069	39.11–1037.36
Covid-19 (-) + TE (-)	617.47 ± 477.88	.069	39.11–1037.36
Covid-19 (-) + TE (+)	1133.38 ± 690.25	.421	746.53–1778.34
Covid-19 (-) + TE (-)	617.47 ± 477.88	.421	746.53–1778.34

SD, Standard deviation; TE, Thrombo-embolism